References to Primarv Literature
- LEVIN ED, ROSE JE et al.: Characterization of the cogni-tive effects of combined muscarinic and nicotinic block-ade. Behav. Neural Biol. (1990) 53:103–112.
- COURT JA, PERRY EK: CNS nicotinic receptors. Possibletherapeutic targets in neurodegenerative disorders. CNS Drugs (1994) 2:216–233.
- QIAN C, LI T et al.: Epibatidine is a nicotinic analgesic.Eur.J. Pharmacol. (1993) 250:R13–R14.
- GLASSCO W, SUCHOCIKI J et al.: Synthesis, optical reso-lution, absolute configuration, and preliminary phar-macology of (+)- and (-) cis-2,3,3a,4,5,91b-hexahydro-l-methyl-lb-pyrrolo[3,2-14isoquinoline, a structural ana-log of nicotine. J. Med. Chem. (1993) 36:3381–3385.
- ARNERIC SP, SULLIVAN JP et al.: (S)-3-methy1-5-(1-methy1-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognitive-enhancing and anxiolytic activi-ties. L In vitro characterization. J. Pharmacol. Exp. 71)er. (1994) 270:310–318.
References to Patent Literature
- ABBOlT LABS., US 5472958 (1995).
- BAYER AG, EP-679397 (1995).
- H LUNDBECK AS, W0%08468 (19%)
- RJ REYNOLDS TOBACCO CO., W09607410 (196)
- CYTOMED., WC. & UNIV. VIRGINIA, W09507078 (1995)